Identification of a novel alternative splicing isoform of the Hippo kinase STK3/MST2 with impaired kinase and cell growth suppressing activities.
Ana Maria RodriguesAna Paula Zen Petisco FioreGabriela D A GuardiaRebeka TomasinAndré Azevedo Reis TeixeiraRicardo Jose GiordanoDeborah SchechtmanMichele PaganoPedro Alexandre Favoretto GalanteAlexandre B CardosoPublished in: Oncogene (2024)
Mammalian Ste-20-like Kinases 1 and 2 (MST1/2) are core serine-threonine kinases of the Hippo pathway regulating several cellular processes, including cell cycle arrest and cell death. Here, we discovered a novel alternative splicing variant of the MST2 encoding gene, STK3, in malignant cells and tumor datasets. This variant, named STK3 ∆7 or MST2 ∆7 (for mRNA or protein, respectively), resulted from the skipping of exon 7. MST2 ∆7 exhibited increased ubiquitylation and interaction with the E3 ubiquitin-protein ligase CHIP compared to the full-length protein (MST2 FL ). Exon 7 in STK3 encodes a segment within the kinase domain, and its exclusion compromised MST2 interaction with and phosphorylation of MOB, a major MST1/2 substrate. Nevertheless, MST2 ∆7 was capable of interacting with MST1 and MST2 FL . Unlike MST2 FL , overexpression of MST2 ∆7 did not lead to increased cell death and growth arrest. Strikingly, we observed the exclusion of STK3 exon 7 in 3.2-15% of tumor samples from patients of several types of cancer, while STK3 ∆7 was seldomly found in healthy tissues. Our study identified a novel STK3 splicing variant with loss of function and the potential to disturb tissue homeostasis by impacting on MST2 activities in the regulation of cell death and quiescence.
Keyphrases
- cell death
- cell cycle arrest
- squamous cell carcinoma
- ejection fraction
- cell proliferation
- induced apoptosis
- signaling pathway
- newly diagnosed
- amino acid
- tyrosine kinase
- end stage renal disease
- cell cycle
- peritoneal dialysis
- protein protein
- high throughput
- prognostic factors
- single cell
- risk assessment
- human health
- patient reported outcomes
- genome wide analysis